---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-052948"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:40:34.087020+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics CFO Salvatore Calabrese departs; severance includes pay and equity acceleration

## Summary
- CFO Salvatore Calabrese terminates April 30, 2023; severance includes €249,827 (12 months' salary) and €41,638 bonus.
- Unvested equity awards accelerate 100% vesting; options exercisable 12 months after termination.
- Additional change-of-control benefits available if triggered before April 30, 2024, less severance paid.
- Mutual non-disparagement and cooperation provisions; full release of claims against the company.

## SEC filing metadata
- accession: 0001104659-23-052948
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465923052948/0001104659-23-052948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465923052948/tm2313505d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-052948
- JSON: https://secwatch.observer/filing/0001104659-23-052948.json
- Plain text: https://secwatch.observer/filing/0001104659-23-052948.txt

## Key facts
- Executive change
  Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: Mr. Calabrese’s employment terminates effective April 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465923052948/0001104659-23-052948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.